Kristen Fortney, BioAge Labs CEO
September 26, 2024 03:11 AM EDT
Financing
Startups

Next-gen obe­si­ty biotech BioAge Labs to raise $198M in IPO

Kyle LaHucik

Senior Reporter

A Cal­i­for­nia biotech that be­gan as an an­ti-ag­ing com­pa­ny, then li­censed an Am­gen heart fail­ure drug for $1 mil­lion up­front and re­pur­posed it as a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times